NCT03919786

Brief Summary

This study intends to explore a new therapy to reduce the incidence of atrial fibrillation in thoracic patient who receive video-assisted thoracoscopic lobectomy .The results of the study are to assess the effects of this new intervention on the incidence,duration of atrial fibrillation and other complications including postoperative delirium after video-assisted thoracoscopic lobectomy .And reducing the burden of POAF on patients and their families, hospitals and public resources.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P50-P75 for not_applicable atrial-fibrillation

Timeline
Completed

Started Apr 2019

Shorter than P25 for not_applicable atrial-fibrillation

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2019

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

April 5, 2019

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 18, 2019

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2020

Completed
Last Updated

December 5, 2019

Status Verified

December 1, 2019

Enrollment Period

1.2 years

First QC Date

April 5, 2019

Last Update Submit

December 3, 2019

Conditions

Keywords

postoperative atrial fibrillationlobectomythoracic surgeryvagus nerve blockpulmonary myocardial sleeve

Outcome Measures

Primary Outcomes (1)

  • incidence of POAF

    Continuous ECG recordings were made on Holter recorders for 72 hours after the operation. Arrhythmia detection were done automatically by template matching. The decisions made automatically by the computer were reviewed and corrected by an experienced technician and then by a cardiologist.

    72 hours after surgery

Secondary Outcomes (33)

  • the Trail Making Test

    1 day before surgery(baseline)

  • the Grooved Pegboard Test

    1 day before surgery(baseline)

  • the Digit Span Test

    1 day before surgery(baseline)

  • the Number-Symbol Replacement Test

    1 day before surgery(baseline)

  • the Finger Tapping Test

    1 day before surgery(baseline)

  • +28 more secondary outcomes

Study Arms (2)

intervention group

EXPERIMENTAL

Durg:0.375% Ropivacaine and 1% lidocaine topical local anesthesia of pulmonary vein with lidocaine+ropivacaine at the beginning and the end of surgery operation. Block vagus nerve with lidocaine+ropivacaine 1ml after exposing the pleural apex

Procedure: topical local anesthesia of pulmonary vein combined with vagus nerve block

normal saline group

PLACEBO COMPARATOR

Same volume of normal saline will be administrated

Procedure: topical local anesthesia of pulmonary vein combined with vagus nerve block

Interventions

Injecting 1% lidocaine 1.5ml+0.375% ropivacaine 1.5ml into vascular sheaths of all pulmonary vein of the surgery side at the beginning of surgery operation. Wrapping all pulmonary vein of the surgery side with cotton sheet infiltrated with 1% lidocaine+0.375% ropivacaine at the end of surgery operation. Blocking vagus nerve above the aortic vein on the right side of the trachea with 1% lidocaine 1ml+0.375% ropivacaine 1ml after exposing the pleural apex.

intervention groupnormal saline group

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Thoracoscopic lobectomy and bilobectomy
  • ASA class I-III
  • Age is greater than or equal to 50 years old
  • Han Nationality, mother tongue is chinese
  • The people signed informed consent

You may not qualify if:

  • history of chronic atrial arrhythmia
  • sick sinus syndrome
  • history of second-degree atrioventricular block
  • taking class I or class III antiarrhythmic drugs or β-receptor blocker
  • history of radiofrequency ablation
  • hyperthyroidism
  • contraindications of ropivacaine, lidocaine
  • pregnancy and lactation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Anesthesiology of the Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China

RECRUITING

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Intervention is not blinded to anesthesiologists and nurses participating intraoperative management.These anesthesiologists and nurses will not participate the follow-up study of this patient.Surgeons performing surgery are blinded.
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Doctor-in-charge of Anesthetist

Study Record Dates

First Submitted

April 5, 2019

First Posted

April 18, 2019

Study Start

April 1, 2019

Primary Completion

May 30, 2020

Study Completion

July 1, 2020

Last Updated

December 5, 2019

Record last verified: 2019-12

Locations